LENT Prognostic Score for Malignant Pleural Effusion
ورودیهای بالینی بیمار
حداقل ۰ — حداکثر ۱۰۰۰۰ • واحد: U/L
حداقل ۰ — حداکثر ۱۰۰
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low Risk0–1
- Moderate Risk2–4
- High Risk5–7
The LENT Prognostic Score for Malignant Pleural Effusion calculator is designed for bedside predicting survival in patients with malignant pleural effusion using clinical and laboratory parameters to help inform treatment decisions and prognosis discussions in clinical practice. The resulting score directly guides clinician decision-making regarding.
Clinical Guidelines & Evidence
Predicts survival in patients with malignant pleural effusion using clinical and laboratory parameters to help inform treatment decisions and prognosis discussions
Clinical Indication
The LENT Prognostic Score for Malignant Pleural Effusion is indicated for bedside clinical practice to support Predicts survival in patients with malignant pleural effusion using clinical and laboratory parameters to help inform treatment decisions and prognosis discussions. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.
Limitations & Contraindications
Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care.
Clinical Pearls & Action Plan
Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival. Guideline pearl: Not meant to replace clinical judgment in treatment decisions.
LENT Score = LDH points + ECOG points + Neutrophil-lymphocyte ratio points + Tumor type points
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| pleural_fluid_ldh | float | Yes | Pleural fluid lactate dehydrogenase (LDH) level(U/L) |
| ecog_performance_status | integer | Yes | Eastern Cooperative Oncology Group (ECOG) Performance Status scale |
| neutrophil_lymphocyte_ratio | float | Yes | Serum neutrophil-to-lymphocyte ratio |
| tumor_type | string | Yes | Primary tumor type |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–1 | Low Risk | Low risk of mortality |
| 2–4 | Moderate Risk | Moderate risk of mortality |
| 5–7 | High Risk | High risk of mortality |
Evidence-Based References (EBM)
- Clive AO, Kahan BC, Hopwood BE, Bhatnagar R, Morley AJ, Zahan-Evans N, et al. Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax. 2014 Dec;69(12):1098-104.
- Psallidas I, Kanellakis NI, Gerry S, Theza A, Saba T, Tsim S, et al. Development and validation of response markers to predict survival and pleurodesis success in patients with malignant pleural effusion (PROMISE): a multicohort analysis. Lancet Oncol. 2018 Jul;19(7):930-939.
- Porcel JM. Malignant pleural effusion. Current opinion in Pulmonary Medicine. 2016 Jul;22(4):356-61.